Weissman EM - Search Results

1

Physical health monitoring of patients with schizophrenia.

Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Marder SR, et al. Among authors: weissman em. Am J Psychiatry. 2004 Aug;161(8):1334-49. doi: 10.1176/appi.ajp.161.8.1334. Am J Psychiatry. 2004. PMID: 15285957 Review.

2

Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics.

Weissman EM, Zhu CW, Schooler NR, Goetz RR, Essock SM. Weissman EM, et al. J Clin Psychiatry. 2006 Sep;67(9):1323-6. doi: 10.4088/jcp.v67n0901. J Clin Psychiatry. 2006. PMID: 17017817

3

Monitoring metabolic side effects when initiating treatment with second-generation antipsychotic medication.

Weissman E, Jackson C, Schooler N, Goetz R, Essock S. Weissman E, et al. Clin Schizophr Relat Psychoses. 2012 Jan;5(4):201-7. doi: 10.3371/CSRP.5.4.4. Clin Schizophr Relat Psychoses. 2012. PMID: 22182457

4

Health monitoring for patients who have schizophrenia. Summary of the Mount Sinai Conference recommendations.

Covell NH, Jackson CT, Weissman EM. Covell NH, et al. Among authors: weissman em. Postgrad Med. 2006 Sep;Spec No:20-6. Postgrad Med. 2006. PMID: 17128658 Review.

5

Weight gain with clozapine compared to first generation antipsychotic medications.

Covell NH, Weissman EM, Essock SM. Covell NH, et al. Among authors: weissman em. Schizophr Bull. 2004;30(2):229-40. doi: 10.1093/oxfordjournals.schbul.a007074. Schizophr Bull. 2004. PMID: 15279042 Clinical Trial.

6

Inside the black box: the importance of monitoring treatment implementation.

Essock SM, Covell NH, Weissman EM. Essock SM, et al. Among authors: weissman em. Schizophr Bull. 2004;30(3):613-5. doi: 10.1093/oxfordjournals.schbul.a007107. Schizophr Bull. 2004. PMID: 15631252 No abstract available.

7

What do people with schizophrenia think about weight management?

Weissman EM, Moot DM, Essock SM. Weissman EM, et al. Psychiatr Serv. 2006 May;57(5):724-5. doi: 10.1176/ps.2006.57.5.724. Psychiatr Serv. 2006. PMID: 16675776 No abstract available.

8

Pharmacoeconomics of antipsychotic medications.

Weissman EM, Essock SM. Weissman EM, et al. Expert Rev Pharmacoecon Outcomes Res. 2002 Feb;2(1):13-21. doi: 10.1586/14737167.2.1.13. Expert Rev Pharmacoecon Outcomes Res. 2002. PMID: 19807425

9

Impact of modifying risk adjustment models on rankings of access to care in the VA mental health report card.

Weissman EM, Rosenheck RA, Essock SM. Weissman EM, et al. Psychiatr Serv. 2002 Sep;53(9):1153-8. doi: 10.1176/appi.ps.53.9.1153. Psychiatr Serv. 2002. PMID: 12221315

10

Evidence-based pharmacologic treatment for people with severe mental illness: a focus on guidelines and algorithms.

Mellman TA, Miller AL, Weissman EM, Crismon ML, Essock SM, Marder SR. Mellman TA, et al. Among authors: weissman em. Psychiatr Serv. 2001 May;52(5):619-25. doi: 10.1176/appi.ps.52.5.619. Psychiatr Serv. 2001. PMID: 11331795 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters